Fascinated by the recent reclassification of repeated low level red light therapy (RLRL) devices in China?
All eye care professionals are invited to join Eyerising for a free webinar and hear first-hand from Professor Junwen Zeng on the reality of the situation in China, and his real-world study of the Eyerising RLRL device for myopia control.
This webinar will:
- Examine real-world studies showcasing patient outcomes,
- Clarify rumours about RLRL, including news of the China reclassification.,
- Discuss clinical evidence underpinning RLRL as a myopia control option, and
- Conclude with an open Q&A with both professors.
Date: 26 March 2025
Time: 6:30 pm AEDT (Melbourne, Sydney, Canberra)
Location: Microsoft Teams Webinar
Register: Online
Professor Junwen Zeng… will share his real-world study of over 1,000 patients on RLRL in China, as well his insights into the use of RLRL beyond reclassification
Speakers
Professor Junwen Zeng
Junwen Zeng is Professor and Chairman of the Refraction and Low Vision Department at Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China where his clinical and research focus is on myopia prevention and treatment. At this webinar he will share his real-world study of over 1,000 patients on RLRL in China, as well his insights into the use of RLRL beyond reclassification.
Professor Mingguang He
Mingguang He is Chair Professor of Experimental Ophthalmology at Hong Kong Polytechnic University, and founder of RLRL. Professor He will join the Q&A session of this webinar to discuss the numerous ongoing studies of RLRL and real-world use in China and beyond.
Register to Attend
Register online to attend the RLRL in China: Real-world Experiences by Eyerising International.
